Patients who test positive using Labcorp's COVID-19 PCR test will receive information about monoclonal antibody therapeutics with their result.
Additionally, Labcorp's COVID-19 site provides information about treatments and vaccines, including monoclonal antibody therapies, and answers a variety of questions related to testing options.
As of May 7, Labcorp has processed more than 41 m COVID-19 PCR tests.
Monoclonal antibody treatments are laboratory-made proteins that mimic the immune system's ability to fight off harmful pathogens such as the virus that causes COVID-19.
Two such treatments currently have emergency use authorization from the US Food and Drug Administration.
People who are at high risk for progressing to severe COVID-19 or hospitalization can potentially reduce their risk of becoming very ill by receiving a monoclonal antibody treatment within the first 10 days of illness.
Early evidence suggests that monoclonal antibody treatments can reduce the amount of SARS-CoV-2, the virus that causes COVID-19, in a person's system, which decreases the likelihood of severe symptoms and hospitalization.
Labcorp's COVID-19 PCR test has not been FDA-cleared or approved; it has been authorized by the FDA under an EUA only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens.
The test is authorized only for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b) (1) of the Act, 21 USC. § 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.
Labcorp has diagnostics and drug development capabilities, more than 70,000 employees, and serves clients in more than 100 countries.
HHS works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT